Evidence map›Paper›PMID 35123336›Full record

ArticleSchizophrenia research2022

Olanzapine, risperidone and quetiapine: Do these atypical antipsychotics have a protective effect for SARS-CoV-2?

Cintia R Prokopez, Romina Farinola, Miguel Vallejos, Lorena S Lopredo, Luciano E Sfriso, Luciana C Chiapella, Claudio Arce, Ricardo M Corral, Manuel J Cuesta, Martín Alomo

Abstract readLetterComment
In one paragraph

Article in Schizophrenia research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Cintia R ProkopezBraulio Aurelio Moyano Neuropsychiatric Hospital, Buenos Aires, Argentina; Institute of Pharmacology, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina. Electronic address: cprokopez@gmail.com.
Romina FarinolaJosé Tiburcio Borda Hospital, Buenos Aires, Argentina.
Miguel VallejosJosé Tiburcio Borda Hospital, Buenos Aires, Argentina.
Lorena S LopredoBraulio Aurelio Moyano Neuropsychiatric Hospital, Buenos Aires, Argentina.
Luciano E SfrisoBraulio Aurelio Moyano Neuropsychiatric Hospital, Buenos Aires, Argentina.
Luciana C ChiapellaNational Scientific and Technical Research Council (Gordon, Jang et al.), Buenos Aires, Argentina; Pharmacology Area, Faculty of Biochemical and Pharmaceutical Sciences, National University of Rosario, Santa Fe, Argentina.
Claudio ArceBraulio Aurelio Moyano Neuropsychiatric Hospital, Buenos Aires, Argentina.
Ricardo M CorralJosé Tiburcio Borda Hospital, Buenos Aires, Argentina.
Manuel J CuestaDepartment of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Martín AlomoBraulio Aurelio Moyano Neuropsychiatric Hospital, Buenos Aires, Argentina; Faculty of Psychology, University of Buenos Aires, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antipsychotic AgentsCOVID-19BenzodiazepinesHumansOlanzapineQuetiapine FumarateRisperidoneSARS-CoV-2Antipsychotic AgentsBenzodiazepinesOlanzapineQuetiapine FumarateRisperidone

Identifiers

PMID35123336
PMCPMC8784573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.